Celerion Lincoln serves as the cornerstone of early-stage clinical research, functioning not only as the company’s global headquarters but also as a high-capacity engine for drug development. Located in the heart of Nebraska, this facility facilitates a critical bridge between laboratory discoveries and the delivery of life-saving medications to the market. For decades, the operations in Lincoln have specialized in complex clinical pharmacology, providing essential data to pharmaceutical and biotechnology companies worldwide.

The Evolution of Medical Innovation in Lincoln

The presence of high-level clinical research in Lincoln is not a recent development. The legacy of the current Celerion facility dates back to 1933, originally established as Harris Laboratories. Initially focused on agricultural and food science testing, the organization pivoted significantly in 1969 to offer clinical research services. This move was revolutionary at the time, helping to define the modern Contract Research Organization (CRO) industry.

Through various transitions—including periods as MDS Harris and MDS Pharma Services—the entity was rebranded as Celerion in 2010. This long-standing history has allowed the Lincoln site to accumulate over 50 years of specific expertise in clinical pharmacology. Today, the facility manages a substantial portion of the company’s global bed capacity and serves as a primary site for specialized studies that many other facilities lack the infrastructure to support.

Core Capabilities: ADME and Radiolabeled Studies

One of the most significant distinctions of Celerion Lincoln is its status as a primary center for Absorption, Distribution, Metabolism, and Excretion (ADME) studies. These trials are fundamental to understanding how a drug is processed by the human body.

Radiolabeled Compound Expertise

Celerion Lincoln is uniquely equipped to handle radiolabeled compounds. Using carbon-14 or other radioisotopes, researchers can track the journey of a drug molecule through the body with extreme precision. The facility features a dedicated onsite ADME suite for pharmacy compounding, certified to rigorous USP <800> and USP <825> standards. This allows for the preparation of radioactive drug products in various forms, including oral solutions, intravenous dosing, and subcutaneous injections.

Real-Time Scintillation Counting

A major advantage of the Lincoln facility is the integration of clinical services and scintillation counting in one location. On-site equipment allows for the measurement of radioactivity recovery in real-time. By analyzing blood, urine, feces, and sometimes expired air, scientists can determine the exact routes of drug excretion. This real-time capability eliminates the delays associated with shipping samples to external labs, often providing recovery data in days rather than weeks. The facility historically maintains an average radioactive dose recovery rate of 94 percent, a benchmark of scientific excellence in the field.

Advanced Bioanalytical Laboratory Services

Beyond the clinical beds, Celerion Lincoln houses a massive bioanalytical laboratory. This lab is essential for supporting both small and large molecule drug development. The laboratory staff provides high-throughput analysis for thousands of samples, measuring drug concentrations and identifying metabolites.

Key services provided by the Lincoln laboratory include:

  • Method Development and Validation: Creating specific assays to detect new experimental drugs.
  • Pharmacokinetic (PK) and Pharmacodynamic (PD) Analysis: Determining how long a drug stays in the system and what effect it has at various concentrations.
  • Immunogenicity Testing: Assessing whether a biological drug triggers an immune response in participants.

Having the laboratory onsite at the Lincoln headquarters allows for a seamless flow of data between the clinic and the analytical teams, which is vital for the safety of "First-in-Human" (FIH) trials where dose escalation decisions must be made quickly based on current data.

Participating in Research: The Volunteer Experience

For many residents of Lincoln and the surrounding areas, Celerion is known as a source of paid clinical trial opportunities. Every year, thousands of participants contribute to medical science by volunteering for these studies. These individuals, often referred to as healthy volunteers, are essential for determining the safety profiles of new medications before they are tested in patients with specific diseases.

The Screening Process

Participation typically begins with an online registration through a secure portal. Prospective participants provide their medical history, which is then reviewed by clinical staff. If an individual matches the criteria for a specific study, they are invited for an in-person screening. This visit usually includes a physical exam, blood work, and an EKG to ensure the volunteer is in good health and meets all safety requirements.

Study Duration and Stay

Clinical trials at the Lincoln facility vary in length. Some require only short outpatient visits, while others involve stays of several nights or even weeks in the clinical unit at 621 Rose Street. During these stays, volunteers are provided with meals, semi-private accommodations, and common areas with entertainment options like movies, games, and high-speed internet. The environment is highly controlled to ensure the integrity of the data collected.

Compensation and Stipends

Recognizing the time and commitment required, Celerion provides financial compensation to participants. Stipends are based on the length of the study and the complexity of the procedures involved. It is common to see studies offering anywhere from $3,000 to over $11,000. These payments are intended to cover travel, time away from work, and the general effort involved in adhering to the study protocol.

Strategic Lincoln Facilities and Partnerships

Celerion’s footprint in Lincoln extends beyond a single building. The organization has strategically expanded to leverage the city’s academic and medical infrastructure.

  1. 621 Rose Street: This is the main clinical research facility and global headquarters. It houses the majority of the clinical beds and the specialized ADME suites.
  2. Nebraska Innovation Campus (NIC): In recent years, Celerion expanded its presence to the University of Nebraska Innovation Campus. This location serves as a hub for participant screening and recruitment, fostering collaboration with university students and faculty while tapping into the region's biotechnology talent.
  3. Bryan Health Collaboration: Celerion maintains a dedicated wing at Bryan Health hospital. This allows for the conduct of more complex studies that may require hospital-grade equipment (such as MRI, PET scans, or CT scans) or specialized medical personnel who are available in a traditional hospital setting. This partnership is particularly useful for Proof-of-Concept (PoC) studies involving specific patient populations.

Therapeutic Areas of Focus

The research conducted in Lincoln spans a wide range of therapeutic categories. Because the facility focuses on Phase I and Phase II trials, it works with drugs designed to treat conditions such as:

  • Metabolic Disorders: Including diabetes, obesity, and lipid disorders.
  • Cardiovascular Health: Trials focusing on hypertension and cardiac safety (TQT studies).
  • Respiratory Diseases: Research into inflammation and lung function.
  • Neurology and Pain: Testing new analgesics and treatments for neurologic conditions.
  • Infectious Diseases: Evaluating vaccines and antiviral medications.

By facilitating research in these areas, the Lincoln team contributes directly to the clinical pharmacology labeling of many drugs that eventually receive FDA approval.

Safety, Ethics, and Regulatory Rigor

The safety of participants is the paramount concern at Celerion Lincoln. Every study conducted is subject to rigorous oversight from several bodies:

  • Institutional Review Board (IRB): An independent committee reviews every study protocol to ensure the rights and welfare of participants are protected. No study can begin without IRB approval.
  • Food and Drug Administration (FDA): As a facility conducting research for drugs intended for the US market, Celerion is subject to regular inspections and audits by the FDA to ensure compliance with Good Clinical Practice (GCP) guidelines.
  • Informed Consent: Before any procedures occur, every volunteer goes through a detailed informed consent process. This involves a thorough explanation of the study’s purpose, the potential risks, the procedures involved, and the participant's right to withdraw at any time for any reason.

The Role of Technology in Modern Trials

As of 2026, Celerion Lincoln has integrated advanced digital tools to enhance both data accuracy and the participant experience. Real-time data capture systems allow researchers to monitor volunteer vitals and laboratory results instantaneously. For participants, mobile applications now streamline the registration and medical history reporting process, making it more efficient to qualify for upcoming studies.

Furthermore, the use of modeling and simulation at the Lincoln headquarters helps clients predict drug behavior in humans based on earlier animal data. This "translational medicine" approach reduces the risk in clinical development and can shorten the timeline for bringing a drug to market.

Conclusion

Celerion Lincoln stands as a vital pillar in the global pharmaceutical landscape. By combining a rich historical legacy with state-of-the-art facilities like the ADME suite and the Innovation Campus expansion, it provides a unique environment for scientific discovery. For the scientific community, it offers unparalleled expertise in clinical pharmacology; for the local Lincoln community, it remains a trusted partner for those looking to contribute to medical progress through clinical trial participation. As drug development becomes increasingly complex, the role of specialized, high-capacity centers like Celerion Lincoln will only continue to grow in importance.